Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
Source: SeekingAlpha
2026-01-29 03:25:39 ET
Read the full article on Seeking Alpha
For further details see:
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
Alvotech
NASDAQ: ALVO
ALVO Trading
-2.37% G/L:
$3.92 Last:
156,058 Volume:
$3.95 Open:
ALVO Latest News
February 05, 2026 03:00:00 am
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
February 02, 2026 03:00:00 am
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
January 29, 2026 03:00:00 am
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
